![Patients with obesity, T2DM or CV comorbidities display an imbalance in the RAAS system and upregulated sDPP4 levels. These 2 factors *per se* increase the risk for bronchoconstriction, lung inflammation, heart failure, endothelial dysfunction, atherosclerosis and immune dysregulation. ACE2 is a receptor for SARS-CoV-2 and DPP4 has been poposed as potential co/receptor. We hypothesize that in patients with these comorbidities, where both ACE2 and sDPP4 are enhanced, infection with SARS-CoV-2 may result in increased COVID-19 severity with pulmonar complications such as ALI, ARDS and CV complications such as heart failure, arrhythmia, myocarditis, endothelitis, oedema and coagulopathy.](fphar-11-01161-g002){#f2}

Introduction {#s1}
============

Diabetes as Promoter of Severity and Mortality in COVID-19 {#s1_1}
----------------------------------------------------------

The recent outbreak of COVID-19 pneumonia in China ([@B37]; [@B44]) has become an urgent health and economic challenge due to its pandemic proportions. Therefore, there is a current race for developing strategies to treat or prevent COVID-19 infection. COVID-19 is caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During the last 20 years other two betacoronaviruses bursted, namely SARS-CoV and middle east respiratory syndrome (MERS)-CoV, yet without such pandemic impact.

Similarly to former influenza infections, there is increasing evidence that diabetes is an important risk factor for the severity and mortality of COVID-19 ([@B43]; [@B52]; [@B131]). A meta-analysis pointed towards hypertension and cardiovascular (CV) disease and diabetes as the most prevalent cardiometabolic comorbidities in COVID-19 hospitalized patients ([@B62]). The first large cohort of hospitalized patients with COVID-19 in Europe confirmed arterial hypertension, followed by chronic heart disease and diabetes as the main comorbidities upon hospitalisation. While at intensive care unit (ICU) the most frequent comorbidities were hypertension, obesity and diabetes ([@B18]; [@B106]). Furthermore, recent studies suggest that obesity may be related to increased COVID-19 severity ([@B80]; [@B99]) even in younger patients ([@B64]).

Being CV diseases the main cause of morbi-mortality in type 2 diabetic patients, it is not surprising that besides being comorbidities, obesity, type 2 diabetes mellitus (T2DM) and CV diseases have been suggested as risk factors for severity in COVID-19 in several meta-analysis ([@B114]; [@B127]). In fact, in a retrospective cohort study including 72.314 COVID-19 patients, those with previous CV comorbidities displayed five-fold higher mortality risk ([@B121]).

Since initial epidemiological data pointed towards COVID-19 specially affecting older patients where diabetes, CV diseases and obesity are frequent comorbidities, it is under discussion whether these comorbidities and especially diabetes actually increase the risk of infection or only the severity or if they are just co-existing preconditions more frequently found in the severely affected patients ([@B21]; [@B28]).

Pathophysiology of COVID-19: Pulmonar and Cardiovascular Complications {#s1_2}
----------------------------------------------------------------------

Acute respiratory distress syndrome (ARDS) is the main death cause of COVID-19 ([@B44]). Autopsy and radiography findings detected acute lung inflammation in patients, characterized by accumulation of infiltrated leukocytes ([@B63]). In fact, one of the main causes for ARDS is the cytokine storm, that results in an excessive inflammatory response. Although macrophages do not allow SARS-CoV replication, interaction of SARS-CoV with these cells leads to overproduction of pro‐inflammatory cytokines potentially leading to acute lung injury (ALI) and ARDS ([@B42]). Besides macrophages, the role of activated endothelial cells is increasingly acknowledged to be implicated in the inflammatory response in ARDS ([@B111]), as alveolar--capillary barrier disruption is the key determinant for the progression of severe hypoxemia shown in COVID-19 patients ([@B62]). Several epidemiological studies suggest that type 2 diabetic patients display increased risk of developing pulmonary hypertension and worse survival ([@B53]).

Although COVID-19 is primarily acknowledged as a respiratory disease, lung damage can be attributable to a great extent to an initial CV cause such as embolism or pulmonary hypertension. Not only CV complications can be a key cause of death in COVID-19, but those patients with previous CV diseases are at increased risk of death ([@B38]; [@B131]).

In fact, CV impairment manifestations are arising as relevant secondary complications during SARS-CoV-2 infection. On one hand, it has been observed that previous CV conditions worsen upon COVID-19 diagnosis ([@B38]), although cerebrovascular accidents have intriguingly been also reported in healthy young patients with no history of chronic conditions ([@B76]).

The main CV complications reported in COVID-19 are myocardial infarction, arrhythmia, stroke and arterial and venous thromboembolism, including pulmonary embolism ([@B25]; [@B115]). The ability of SARS-CoV-2 to directly infect other cells beyond the lung epithelium causing myocarditis and endothelitis might be the underlying explanation, but also an exacerbated immune and/or coagulation response. SARS-CoV-2 can induce, as other SARS-CoVs, direct damage on the cardiomyocytes, in line to reported interstitial monoculear inflammatory cells infiltration in the myocardium of COVID-19 positive patients ([@B123]). In fact, cardiac injury has been reported in about 20% of the analysed patients ([@B38]; [@B131]).

A retrospective case series analysing 187 patients in Wuhan observed that patients with underlying CV disease were the ones presenting more severe heart damage, as indicated by elevated troponin T (TnT) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels ([@B22]; [@B38]). Indeed, high NT-pro-BNP levels in critially ill patients was also associated with acute respiratory symptoms and increased inflammatory status ([@B125]). Equally, patients with no preexisting heart conditions have shown signs of cardiac damage ([@B62]).

Endothelitis was also evidenced by postmortem electron analysis of viral inclusion structures in renal endothelial cells ([@B109]). In fact, SARS-CoV-2 was able to directly infect engineered human blood vessel organoids *in vitro* ([@B71]). Accumulated inflammatory cells and apoptotic bodies near vascular beds ([@B109]) lead to altered vascular permeability ([@B25]), an important sign of endothelial dysfunction. Endothelial dysfunction is a hallmark of CV disease found in hypertension, diabetes and obesity. However, SARS-CoV-2 might impair endothelium functionality not only on those patients with previous weakened vasculature, but also in healthy individuals. There are case-reports of patients under 50 presenting sudden strokes even with mild manifestations of COVID-19 onset ([@B76]).

Coagulopathy has been diagnosed in several fatal and non-fatal cases, with a number of thrombotic parameters altered in COVID-19 patients, including anti-thrombin activity (AT), pro-thrombin time (PT) and D-dimer ([@B115]; [@B127]). Reported higher D-dimer levels paralleled massive elevation of pro-coagulant von Willebrand factor and factor VIII, indicating endothelial activation ([@B26]). Endothelial activation leads to chemokine and cytokine release resulting in recruitment of immune cells, perpetuating and spreading inflammation to neighbouring tissues. In fact, a retrospective analysis of the coagulation features in 183 patients determined that fatal COVID-19 cases displayed disseminated intravascular coagulation ([@B102]), which is strictly linked to endothelial dysfunction and reinforces the sense of SARS-CoV-2 deteriorating endothelium in the lung and beyond.

Thus, CV complications might represent cause and effect of pulmonary manifestations of COVID-19. Microvascular dysfunction of lung capillaries implies the development of pulmonary oedema due to increased vascular permeability, which also allows SARS-CoV-2 to invade other vascular beds ([@B109]). In the same way, clots coming from peripheral vessels can migrate to the lungs or even the brain and cause pulmonary thromboembolism or strokes. In fact, evidence in both animals and humans has demonstrated that fibrinolytic therapy in ARDS and ALI improves survival ([@B116]). Therefore, vascular function preservation in COVID-19 treatment, and more specifically, in diabetic patients might improve the disease prognosis.

Angiotensin-converting enzyme-2 (ACE2) is a pivotal protein in the protecting branch of the renin-angiotensin-aldosterone system (RAAS), as it metabolizes angiotensin (Ang) II into its physiological antagonist Ang-(1-7), which oposses its detrimental vascular effects ([@B91]). In fact, type 2 diabetic patients display an umbalanced AngII/Ang-(1-7) ratio ([@B100]). Analogously, DPP4 upregulation has been associated with vascular pathophysiology in diabetes and obesity ([@B87]; [@B120]). We hypothesize that enhanced circulating levels of soluble DPP4 and misbalanced ACE2 expression found in obesity and T2DM may contribute to the severity of COVID-19 related to these disease/comorbidities. Furthermore, due to their vascular effects, both DPP4 and ACE2/Ang II axis arise as potential therapeutic targets to ARDS and CV complications in COVID-19 that might be pharmacologically scoped, as it will be detailed below.

Mechanisms of SARS-CoV-2 Entry Into Host Cells {#s2}
==============================================

Similarly to SARS-CoV, it has been proposed that SARS-CoV-2 enters human cells using ACE2 as receptor ([@B128]). Once attached to ACE2 *via* the receptor binding domain (RBD) in the viral spike protein, it is primed by the host serine protease TMPRSS2, which ultimately allows fusion of viral and cellular membranes. Although ACE2 is ubiquosly expressed, with higher expression in the CV system, within the lung it is specifically found in alveolar epithelial cells and lung endothelial cells ([@B91]).

In the lung, SARS-CoV infects mainly pneumocytes and macrophages ([@B97]). The peptidases in the lung epithelium and endothelium have been proposed as primary sites for coronavirus infection once the viral infection progresses in the respiratory tract. In this line, it has been suggested that the use of peptidases by coronaviruses to enter host cells might rely more on their abundance than on their proteolytic activity ([@B59]). However, the specific proteins that facilitate SARS-CoV-2 entry in host cells remain unclear.

It has been suggested that other betacoronavirures require the participation of diverse surface proteins for human cells invasion. Thus, sialic acid receptors and C-type lectin receptor CD209/DC-SIGN, expressed on the surface of macrophages and dendritic cells, participate in SARS-CoV invasion into immune cells *in vivo* ([@B59]; [@B54]). *In vitro* the transmembrane glycoprotein CD147/basigin has been described to mediate SARS-CoV invasion. Interestingly, the interaction of CD147 and SARS-CoV-2 RBD has been observed and successfully prevented by competitive anti-CD147 treatment ([@B117]).

On the other hand, MERS-CoV binds to human DPP4/CD26 to infect host cells ([@B85]). A very recent study predicting the structure of the SARS-CoV-2 spike glycoprotein and its glycan shield pattern suggests that DPP4/CD26 may also act as receptor for SARS-CoV-2 ([@B108]). In favor of this hypothesis lays the highest co-expression of DPP4 with ACE2 ([@B84]). In fact, unique residues of SARS-CoV-2 glycoprotein predicted to bind ACE2 can also interact with DPP4 ([@B108]).

Since MERS-CoV binds to DPP4, a transgenic mouse model expressing human DPP4 on relevant cells as epithelial and alveolar pulmonary cells has been used to study the impact of diabetes on MERS-CoV infection. MERS-CoV-infected diabetic mice expressing DPP4 suffered more severe symptoms for longer time than corresponding infected controls ([@B55]). Therefore, we hypothesize that DPP4 might represent a link between diabetes and morbi-mortality/severity of COVID-19.

RAAS and sDPP4 in Diabetes and Other Comorbidities {#s3}
==================================================

Cardiovascular Effects of ACE-Ang II-AT1R Axis Upregulation and Ang-(1-7)/Mas Axis Dowregulation {#s3_1}
------------------------------------------------------------------------------------------------

The RAAS is a key player in the regulation of CV homeostasis in both health and disease. Ang II is the primary effector of RAAS, upregulated in the context of vascular pathophysiology exerting vasoconstrictor, pro-oxidant, pro-inflammatory, pro-fibrotic and proliferative effects, mostly through AT1 receptors ([@B90]). ACE2 is a pivotal protein in the protecting branch of RAAS, as it metabolizes Ang II into Ang-(1-7) and Ang I into Ang-(1-9) which is in turn metabolized as Ang-(1-7) by angiotensin-converting enzyme (ACE). Ang-(1-7) opposes to Ang II-induced detrimental vascular effects participating in vasodilator, anti-inflammatory, anti-oxidant, anti-proliferative, anti-thrombotic and anti-senescence responses through Mas receptors ([@B91]; [@B90]). Moreover, Ang-(1-7) stimulates pleiotropic cytoprotective pathways (Nrf2-HO-1 axis) ([@B90]) ([**Figure 1**](#f1){ref-type="fig"}).

![Diagram summarizing the main physio- and pathophysiological functions of ACE2 and DPP4, their potential contribution to CV complications in COVID-19 as well as potential therapeutic strategies interfering with these 2 factors to counteract CV complications in COVID-19 and type 2 diabetic patients.](fphar-11-01161-g001){#f1}

Under physiological conditions, the RAAS peptides are produced in a balanced manner, whereas misbalance of the RAAS has been implicated in arterial hypertension and diabetes. It has been proposed that increased Ang II can contribute to hyperglycaemia and dyslipidaemia, impairment of vascular function and inflammation. ACE2 deficiency increased vascular inflammation and atherosclerosis in ApoE knockout mice ([@B103]). In fact, ACE2-Ang-(1-7)/Mas axis was shown to participate in the reduction of obesity-induced inflammation and chronic renal failure ([@B91]). In addition, Ang-(1-7) can exert anti-inflammatory effects over RAAS-independent pro-inflammatory stressors as interleukin (IL)-1β ([@B110]; [@B90]).

SARS-CoV spike glycoprotein injection into mice decreased ACE2 expression levels, worsening lung injury ([@B54]). Similarly, SARS-CoV-2-ACE2 binding induced ACE2 internalization ([@B128]), resulting in Ang II accumulation and insufficient Ang-(1-7) synthesis. Importantly, ACE2 is also directly down-regulated by pro-inflammatory cytokines ([@B57]). ACE2 serves both as entry receptor and protective mediator in the lung ([@B71]), in concordance with data observing decreased ACE2 expression and activity in human idiopathic pulmonary fibrosis ([@B60]). Taking that ACE2 is highly expressed in the endothelium and heart ([@B91]), decreased ACE2 levels may also lead to imbalanced RAAS signalling and potential disruption of CV homeostasis in COVID-19 patients.

Cardiovascular Effects of sDPP4 Upregulation {#s3_2}
--------------------------------------------

DPP4/CD26 is a serine protease cleaving a wide variety of substrates including the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP), cytokines and growth factors ([@B87]). DPP4 can be found as a membrane-bound form or be shedded as a soluble form (sDPP4) that maintains its enzymatic activity ([@B87]). We hypothesize that enhanced circulating sDPP4 may promote T2DM-related severity of COVID-19.

In the context of obesity and T2DM, both AT and liver have been proposed as relevant sources of sDPP4 in humans, although the main source remains under discussion. Our group identified sDPP4 as a novel adipose-derived factor ([@B56]), whose circulating levels are enhanced in visceral fat from obese and insulin-resistant patients and correlate with BMI ([@B94]). While sDPP4 plasma activity and levels have been associated with liver apoptosis, fibrosis, fat content, and NAFLD ([@B13]; [@B89]).

DPP4 can promote local and systemic inflammation through its immunomodulatory activity. Thus, DPP4 triggers T cell activation, proliferation and cytokine production alone ([@B30]) or through the interaction with immune partners on antigen presenting cells as CD45, caveolin-1, manose-6 phosphate receptor, or adenosine deaminase (ADA) ([@B87]; [@B118]) ([**Figure 1**](#f1){ref-type="fig"}). DPP4 expression is enhanced on blood T lymphocytes from type 2 diabetic patients and correlates with insulin resistance and glycated hemoglobin ([@B58]). sDPP4 treatment enhanced LPS-induced tumor necrosis factor (TNF)-α and IL-6 secretion in activated monocytes. Besides its upregulation in T2DM and obesity, DPP4 expression is increased in senescent cells ([@B49]).

Immunomodulatory effects of DPP4 have been also demonstrated in animal models. Exogenous injected sDPP4 increased monocyte migration *in vivo* in a model of low-density-lipoprotein receptor-deficient mice. Interestingly, upregulation of DPP4 in obese and diabetic animals have evidenced also its role on immune responses dysregulation. In this regard, genetic depletion of DPP4 improved adipose tissue inflammation in dark agouti rats ([@B87]; [@B89]).

Some DPP4 substrates with CV impact are upregulated in obesity and/or T2DM as well as in COVID-19 such as CXCL5/RANTES and BNP ([@B73]; [@B2]). In fact, high BNP levels were positively correlated with the incidence of CV events and mortality in HIV-infected patients, and was suggested as an indicator of patients condition deterioration from mild to severe prognosis also in COVID-19 ([@B125]).

DPP4 is also known to interact with extracellular matrix (ECM) proteins, participating in both cell migration and tissue remodelling. By binding to fibronectin, DPP4 can promote T cell helper migration and accummulation in areas with increased ECM proteins, such as damaged blood vessels ([@B6]). DPP4 also interacts with fibroblast activation protein (FAP)-α/seprase leading to migration and invasion of endothelial cells into collagen matrices ([@B33]). Moreover, stromal cell-derived factor alpha (SDF-1α) is also a substrate of DPP4, and inhibition of DPP4 has been observed to increase SDF-1α/CXCR4-induced mobilization of endothelial cells from bone marrow to injured vascular sites ([@B6]).

Via its interaction with ADA, DPP4 activates plasminogen-2 leading to increased plasmin levels which contributes to degradation of ECM proteins and the activation of matrix metalloproteinase (MMP)-4, which facilitates immune cells migration and diapedesis ([@B48]; [@B87]). It has been recently proposed that plasmin among other proteases may cleave a new furin site in the spike protein of SARS-CoV-2, leading to an increase in infectivity and severity. This excess of plasmin may contribute to the hyperfibrionolysis resulting in enhanced D-dimer in severe patients ([@B47]).

Importantly, besides its immunomodulatory effects, sDPP4 can exert direct deleterious effects on the vascular wall. sDPP4 directly promoted human smooth muscle cell (hVSMC) proliferation and inflammation *via* NF-κB activation resulting in the upregulation of pro-inflammatory cytokines such as monocyte chemoattractant protein (MCP)-1, IL-6 and IL-8, through a novel mechanism mediated by the activation of the protease activated receptor (PAR)-2 ([@B119]). DPP4 is itself expressed in the vasculature ([@B130]). In hVSMC DPP4 shedding is stimulated by hypoxia in parallel to MMP-1 expression ([@B86]). Moreover, PAR2 activation induced by sDPP-4 triggered endothelial dysfunction in mesenteric microvessels through thromboxane A2 release mediated by cyclooxygenase (COX) and the thromboxane A2 receptor (TP) activation ([@B88]).

Thus we hypothesize that DPP4 expression may contribute to T2DM-related severity of SARS-CoV-2 infection. Furthermore, due to its vascular effects, sDPP4 arises as a potential contributor to ARDS severity by potentially inducing inflammation and bronchoconstriction.

Therapeutic Potential of RAAS-Targeted Drugs in Diabetic Patients With COVID-19 {#s4}
===============================================================================

ACEis and ARBs {#s4_1}
--------------

Despite the initial concerns about ACE inhibitors (ACEi) and AT1 receptor blockers (ARB) treatment potentially predisposing patients to SARS-CoV-2 infection and/or increased COVID-19 severity, the European Medicines Agency advised to continue those prescriptions (EMA/143324/2020; EMA/284513/2020). ACEi/ARBS are primarily prescribed for treating hypertension and associated left ventricular dysfunction, employed in about 35% of the hypertensive population in China ([@B106]).

SARS-CoV-2-ACE2 binding leads to ACE2 downregulation and concomitant misbalance of Ang II/Ang-(1-7) ratio towards Ang II-induced detrimental effects. Ang II binding to AT1 receptors increases pulmonary vascular permeability contributing to lung pathology, as previously shown in relation to SARS-CoV lethality ([@B54]). Some reports observed that ACEi fail to inhibit ACE2 ([@B105]) and suggested that small peptide specific ACE2 inhibitors as DX600 as more efficient inhibiting SARS-CoV cell entry *in vitro* ([@B39]). Nevertheless, ACEi or AT1R may induce ACE2 upregulation as detected both in animal models at mRNA and protein level ([@B101]), as well as urinary excretion in olmesartan-treated hypertensive patients ([@B31]). Taking that increased ACE2 expression also leads to increased Ang-(1-7) production, chronic ACEi and ARB may protect COVID-19 patients. A former study showed that ARB prevented ALI damage in SARS-CoV-infected mice ([@B54]). Accordingly, previous studies have shown that ACEi treatment is associated with a diminished risk of pneumonia in both type 1 and type 2 diabetic patients ([@B107]).

In this line, recent studies have demonstrated that the risk of severe COVID-19 was decreased in patients taking ARB in comparison to no-hypertensive patients ([@B66]; [@B70]). Interestingly, ACEi/ARB-treated COVID-19 positive patients displayed lower concentrations of CRP and procalcitonin ([@B126]), suggesting that the benefit of ACEi and ARB might rely on their anti-inflammatory effects. Indeed, ARB treatment in rats reduced plasma TNF-α, IL-1β and IL-6 levels and increase IL-10 ([@B98]). The ongoing clinical trial BRACE-CORONA (NCT04364893) will compare the impact of temporary discontinuation of ACEi or ARB on mortality and days of hospital stay on patients with SARS-CoV-2 infection ([@B65]).

Ang-(1-7) Analogues {#s4_2}
-------------------

Restoring the balance between the RAAS peptides may be an efficient pharmacological approach against COVID-19. The loss of protective Ang-(1-7) as a result of reduced ACE2 availability, may exaggerate the hyper-inflammatory environment in the lung and beyond. Ang-(1-7) supplementation may reveal as an effective pharmacological strategy to attenuate severe CV complications in COVID-19, as we have recently hypothesized ([@B79]). In animal models of ALI and ARDS, Ang-(1-7) has demonstrated anti-inflammatory and anti-fibrotic effects via, at least in part, the G protein-coupled receptor Mas ([@B50]; [@B91]). Accordingly, administration of Ang-(1-7) and its synthetic analogue AVE 00991 have been reported to reduce leukocyte adhesion to the microvascular endothelium in a model of arthritis ([@B98]).

Indeed, the COVID-ARA2 (NCT04337190) and ATCO clinical trial (NCT04332666) will evaluate Ang II blockade and Ang-(1-7) supplementation in the context of lung disease in COVID-19 patients.

rhACE2 as Decoy Factor {#s4_3}
----------------------

It has been demonstrated that recombinant human ACE2 (rhACE2), already tested in phase 2 clinical trials for ARDS/ALI treatment (NCT01597635), blocks SARS-CoV-2 infection in Vero cells and binding to both human blood vessels and human kidney organoids ([@B71]). Indeed, the recombinant sACE2 drug will be used in an interventional clinical trial over 200 COVID-19 patients (APN01-COVID-19, NCT04335136).

However, rhACE2 has been suggested not only to hamper SARS-CoV-2 entry into host cells but also potentially to protect from lung injury and vascular dysfunction. ACE2 administration lowered blood pressure and improved endothelial function in an Ang-(1-7)-mediated manner in a model of spontaneously hypertensive stroke-prone rats (SHSPR) ([@B30]). In this line, direct activation of ACE2 by NCP-2454 improved pulmonary arterial compliance in a model of pulmonary hypertension ([@B40]). Moreover, administration of rhACE2 normalized Ang II levels in isolated human hearts with dilated cardiomyopathy ([@B12]).

Therapeutic Potential of Targeting DPP4 in Diabetic Patients With COVID-19 {#s5}
==========================================================================

Gliptins {#s5_1}
--------

During COVID-19 infection vascular functionality is endangered. Therefore, preservation of vascular integrity might be a key priority. In case DPP4 represents a link between diabetes and the severity of COVID-19, DPP4i may hold additional therapeutic value to protect diabetic patients suffering COVID-19, as recently especulated ([@B24]; [@B45]).

DPP4i, the so-called gliptins, are antidiabetic drugs based on the control of glucose homeostasis through inhibition of DPP4 enzymatic activity. DPP4 cleaves and inactivates the incretin hormones GLP-1 and GIP, which account for up to 60--70% of postprandial insulin release. This way DPP4i prolong the half life of incretins. Besides its action on incretins, gliptins have been proposed to exert other off-target effects including CV effects. Regarding DPP4 inhibition as a therapeutic strategy to treat and prevent CV diseases in obese and/or type 2 diabetic patients there is still an ongoing discussion. Importantly, gliptins are preferred as add-on therapy in individuals with diabetes coursing with previous chronic kidney disease or additional CV disease ([@B41]).

CV safety of gliptins has been confirmed in several CV outcome trials (SAVOR TIMI 53, NCT01107886; EXAMINE, NCT00968708; TECOS, NCT00790205; CARMELINA, NCT01897532). In relation to their glycemic action, gliptins have demonstrated no risk of hypoglycemic episodes, neutral influence on body weight and a significant reduction of glycated hemoglobin levels (HbA1c), which are important factors associated with reduced CV risk and mortality ([@B132]). Moreover, DPP4i have positive effects over surrogate vascular endpoints, namely blood pressure, lipemia and endothelial function, albeit these CV outcome trials failed in demonstrating additional benefits of gliptins on major CV events ([@B92]). However, gliptins are widely used as T2DM treatment. It has been shown that combined metfomin and gliptin therapy significantly decreased the relative risk of non-fatal CV events, CV mortality and all-cause mortality, in comparison to other oral antihyperglycemic drugs as sulfonylureas ([@B113]).

Preclinical studies have shed light on the mechanisms by which gliptins might improve CV functionality. Increased bioavailability of substrates of DPP4 such as GLP-1 confers indirect cardioprotective effects to gliptins. Beyond GLP-1, DPP4 inhibition increases the effects of other substrates with cardiovascular impact. T2DM patients trated with sitagliptin displayed higher SDF-1α plasma levels resulting in increased endothelial progenitor cells (EPCs), which play a key role in vascular repair ([@B27]). *In vitro*, SDF-1α was also able to improve blood flow in a model of peripheral artery disease ([@B93]). Equally, an increase in BNP improved the regulation of natriuresis and the vasodilatory responses ([@B19]).

In our hands, both hVSMC proliferation and inflammation as well as *ex vivo* endothelial dysfunction exerted by sDPP4 were equally prevented by the experimental and clinically available DPP4i K579 and linagliptin, respectively ([@B119]; [@B88]) That suggests that these drugs may add CV benefit beyond regulating glucose homeostasis and in a GLP-1-independent manner.

In animal models of diabetes, gliptins have also proven protective effects. Vildagliptin-treated streptozotocin (STZ)-induced diabetic rats presented reduced oxydative stress and ICAM-1 and plasminogen activator inhibitor type-1 (PAI-1) expression ([@B67]). In db/db mice linagliptin improved cardiac dysfunction by reducing the activation of the Nlrp3/ASC inflammasome and the upregulation of collagen-1 and collagen-3 ([@B17]). Similarly, sitagliptin also improved cardiac function in mice ([@B81]). Anti-oxidant properties of DPP4i have been also shown under acute inflammation in a mouse model of LPS-induced sepsis ([@B14]).

In type 2 diabetic patients, sitagliptin treatment reduced the molecular markers of inflammation as CRP and IL-6 in mononuclear cells ([@B68]), as well as circulating levels of TNF-α, IL-1β, IL-6, intracellular adhesion molecules and CRP ([@B104]). Sitagliptin also impoved the flow-mediated vasodilation in diabetic adults ([@B11]). Importantly, sitaglipitin conferred cardioprotection in diabetic patients with chronic kidney disease (CKD) reducing the Ang II/Ang-(1-7) ratio ([@B15]).

Gliptins can preserve endothelial function by their reported anti-inflammatory, anti-oxidant and potentially protective effects on the vascular system ([@B9]), which are beneficial aspects in the fight against COVID-19. Additionally, a meta-analysis of large randomized clinical trials demonstrated that gliptin treatment did not increase the risk of general infections in type 2 diabetic patients ([@B124]).

Besides offering potential CV protection, gliptins might be also employed to restrain SARS-CoV-2 binding to host cells. DPP4i ability to hamper coronavirus entry to host cells has been studied. Sitagliptin, vildagliptin or saxagliptin could not block MERS-CoV access to Vero cells ([@B85]). Contrarily, sitagliptin was able to hamper MERS-CoV infection in macrophages by reversing the immunosuppressive capacity of the virus ([@B3]).

All approved gliptins are competitive reversible inhibitors of DPP4 enzymatic activity ([@B23]). However, gliptins can be categorized in 3 classes based on the subsites within the DPP4 molecule they occupy. Class 1 comprises peptidomimetic DPP4i with the most basic binding to DPP4 such as vildagliptin and saxagliptin. While class 2 inhibitors (alogliptin and linagliptin) and class 3 inhibitors (sitagliptin and teneligliptin) display an increased number of interacting points. The more interacting points the higher inhibitory potency ([@B72]). DPP4 extracelullar structure consists of two domains comprised of a eight γ-bladded β-propeller domain and a C-terminal α,β-hydrolase domain with the catallytic triad (Asp708, His740, Ser630) ([@B87]). Conserved aminoacids on DPP4 catalytic site are displayed in pockets S1 and S2. However, the catalytic pocket does not colocalize with the proposed binding sites of SARS-CoV-2 to DPP4 ([@B108]). Nevertheless, previous structural studies regarding MERS-CoV-DPP4 interaction demonstrated that residues in the β-propeller domain of DPP4 (Arg54--Asn497) were essential for virus S1 glycoprotein binding, and some of them are also shared by SARS-CoV-2 ([@B108]).

The residue Asp542 was ascertained as a binding point of SARS-CoV-2 to DPP4, as it was also demonstrated for MERS-CoV ([@B108]). Interestingly, class 1 and 2 gliptins (saxagliptin, alogiptin and linagliptin) are able to bind near this residue (Tyr547) in a zone beyond DPP4 pockets S1 and S2 called S1' subsite ([@B72]). Uracil ring of alogliptin and linagliptin cause a conformational change on DPP4 S1' subsite hampering its enzymatic activity ([@B72]). Therefore, this type of xhantine-based non-peptidomimetic gliptins could potentially impair SARS-CoV-2 binding to one of its preferred sites in DPP4. In addition, linagliptin, and to a lesser extent vildagliptin, have been predicted to bind ACE2 with same or even better binding energy than they have for DPP4 ([@B1]), suggesting additional benefit as SARS-CoV-2 therapy. Whether if more complex class 3 gliptins could exert a steric hindrance to SARS-CoV-2 acess into DPP4 needs further investigation. In this line, a very recent approved clinical trial SIDIACO (NCT 04365517) will study the clinical response of T2DM patients with COVID-19 treated with sitagliptin.

DPP4 immunomodulatory function raises the question whether DPP4i might alter the immune response in diabetic patients ([@B96]). The pharmakokinetic and pharmacodynamic properties of DPP4i allow that DPP4 enzymatic activity in tissues and circulation is not completey blocked ([@B24]). Both DPP4 inhibition with des-fluro sitagliptin and genetic deletion of DPP4 in mice did not alter T-cell dependent immune responses ([@B112]). Sitagliptin, vildagliptin and saxagliptin did not alter innate immune response triggered by Toll-like receptor (TLR) activation in terms of secretion, co-stimulation, T cell proliferation and migration in human cells *in vitro* and in mice *in vivo* ([@B16]).

An initial meta-analysis reported that although DPP4i is not associated with an increased risk for respiratory infections they could increase the risk of urinary tract and nasopharyngitis infection ([@B4]). A more recent meta-analysis assessing the impact of long term use of sitagliptin in T2DM patients determined that there was not an enhanced risk of infection ([@B34]). Another study compared the risk of respiratory tract infections among glucose-lowering therapies and found no increased risk linked to DPP4i in T2DM patients ([@B32]). However the potential induction of leucopenia ([@B82]), angioedema ([@B35]) or cough in asthma ([@B10]) by DPP4i represent potential pitfalls to their use as therapy in COVID-19 ([@B83]). Although 14 years after the approval of DPP4i there have not been major safety issues related to long term use of gliptins. Nevertheless further clinical research will help determine if DPP4i can affect infection risk, T cell development and immune homeostasis in T2DM ([@B51]).

sDPP4 as Soluble Decoy Factor {#s5_2}
-----------------------------

Exogenous administration of sDPP4 inhibited MERS-CoV infection in VERO cells ([@B85]). Therefore, in case it is demonstarted that SARS-CoV-2 can bind DPP4, exogenous acute administration of sDPP4 as a decoy factor to compete for binding of the virus to endogenous DPP4 in COVID-19 target tissues could be explored.

sDPP4 load benefit might not only rely on virus trapping but also on the blockade of detrimental pathways affecting/worsening immune responses and importantly, to potentially prevent COVID-19 effects on the vasculature. In this line, exogenous administration of sDPP4 was effective to bind to ADA and prevent the formation of endogenous DPP4/CD26-ADA complex in human dendritic cells/macrophages resulting in impeded activation and proliferation of T-cells *in vitro* ([@B129]). Disruption of RANTES/CCL5-CCR5 axis with the anti-CCR5 antibody leronlimab reduced IL-6 plasma leves and plasma viral load in COVID-19 patients ([@B78]). It has been proposed that sDPP4 may directly truncate CCL5/RANTES impeding its union to CCR5 ([@B46]) therefore sDPP4 may potentially cause the same effect as leronlimab treatment, leading to an improved immune response and reduced cytokine storm.

In the case of diabetic patients where significantly increased sDPP4 plasma concentration are already present ([@B94]), the potential risk-benefit of exogenous administration of sDPP4 as decoy factor should be carefully investigated.

Anti-DPP4 Vaccine {#s5_3}
-----------------

Another therapeutic approach proven succcesful to regulate plasma DPP4 activity in mice is anti-DPP4 vaccination. Anti-DPP4 vaccine did not cause any side effect on immune cell activation nor immune-mediated attack towards DPP4-expressing cells or tissues. Furthermore it was able to reach comparable effects to gliptin treatment in regard to glycaemia control and GLP-1 plasma levels in mice models of both type 1 and type 2 diabetes ([@B77]; [@B61]). In this line, a humanized IgG1 monoclonal antibody (YS110) with high affinity for CD26 was evaluated in a phase I clinical trial, with demonstrated no effect on T-cell proliferation and cytokine production *in vitro* on human CD26-positive lymphocytes ([@B5]). Interestingly, YS110 also inhibited MERS-CoV infection ([@B75]). However, it has been discussed that *in vivo* administration of anti-DPP4 antibodies could neutralize plasma sDPP4 before it can coate cellular DPP4 and impede virus entry. In this situation, intranasal application of sDPP4 or anti-DPP4 antibodies has been presented as a plausible solution to overcome such effects ([@B122]).

On the other hand, DPP4/CD26-related signaling was successfully blocked by the soluble fusion protein Caveolin-Ig, which demonstrated additional immunosuppresive effects ([@B74]). Tissue-factor pathway inhibitor (TFPI) is a biological blocker of DPP4. Morever, due to its anticoagulant properties ([@B69]), TFPI could be seen as a positive aspect in the context of COVID-19 treatment, albeit potential clinical applications have to be carefully evaluted due to its reported role in cancer ([@B29]).

Combined Therapeutic Potential Targeting RAAS and DPP4 {#s6}
======================================================

DPP4 signalling and RAAS dysregulation bidirectional crosstalk has been proposed previously. Ang II was able to induce DPP4 activity *in vitro* and *in vivo* ([@B7]). Equally, DPP4 inhibition counteracted RAAS overestimulation in a model of renal ablated rats, where sitagliptin treatment increased Ang-(1-7) and ACE2 expression and activity and reduced AT1 receptor expression and Ang II levels ([@B15]). Thus it has been proposed that DPP4i can attenuate the progression of CV disease by opposing RAAS negative effects.

ACE2 and DPP4 present common features as endopeptidases even sharing a wide variety of experimental inhibitors ([@B1]). Hence, the idea of combining inhibitory properties of ACEi and DPP4i against COVID-19 could be appealing. However, it has been observed that DPP4i therapy, when combined with high-dose ACEi, could counter the blood pressure lowering effect of ACEi ([@B6]). Combination of ACEi and DPP4i seems unreasonable due to reported production of angioedema upon coadministration ([@B20]). Angioedema is a potentially fatal adverse reaction as characteristic swelling is generally located around face and neck endangering block of upper airways. Both proteases ACE2 and DPP4 have the capacity to proteolyze bradykinin and substance P leading to accumulation of such vasoactive kinins inducing vasodilatation and increase in vascular permeability ([@B20]). Contrarily, single ACEi or gliptin-associated angioedema is rare (0.1--0.7%) and in some cases disappeared after changing to a different type in the same drug class.

On the other hand, it has been suggested that combination of ARB and DPP4i holds a more effectve therapy for the management of hypertension, renal function and glycaemic control in T2DM ([@B6]). The combination of linagliptin and telmisartan induce sinergistic protective effects in the CV functionality of nephrectomized rats ([@B15]).

Therefore, against SARS-CoV-2 the combination of virus entry blockers (ACEi or DPP4i) and virus capturing decoy factors (rhACE2, sDPP4) would be a better option. However, new perspectives into de design of multitarget drugs holds an important therapeutic oportunity as demonstrated by the synthesis of an enalapril-sitagliptin merged compound, which exhibited dual inhibitiory action against human ACE and DPP4 ([@B1]), with expected reduced drug-drug interactions and undesirable side effects. Moreover, a milk-derived heptapeptide was found to bind and inhibit both ACE and DPP4 activity ([@B8]).

Conclusion {#s7}
==========

Obese and type 2 diabetic patients are at higher risk of SARS-CoV-2 severity since both conditions favour CV complications *per se*. Therefore, in the meantime vaccines are being developed and anti-viral drugs are investigated, therapeutic strategies to fight COVID-19-induced CV alterations are urgently needed.

It is well known that in T2DM and the metabolic syndrome there is a counterbalance in the RAAS system. Therefore, strategies aiming to regulate this counterbalance may be a useful pharmacological strategy to prevent endothelial cell activation and lung damage in COVID-19 ([**Table 1**](#T1){ref-type="table"}). Some studies suggest that ARB and ACEi may also contribute to increase Ang-(1-7) and reduce the risk of severity of COVID-19. Another potential strategy is to provide direct Ang-(1-7) supplementation with analogues to attenuate severe cardiovascular complications in COVID-19 as recently published by us ([@B79]). The role of ACE2 as SARS-CoV-2 receptor, may lead to reduced ACE2 availability and potentially resulting in hyperinflammation. The use of rhACE2 as decoy receptor deserves further investigation.

###### 

Summarized effects of RAAS-targeted drugs (ACEi, ARBS, Ang-(1-7) analogues and rhACE2) reported in preclinical (*in vivo* and *ex vivo*) and clinical research.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Preclinical data                                                                                                                                       Previous clinical trials                                                                                                                                                                                                     COVID-19                                                                                                                                   
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **ACEi**\                 Block SARS-CoV entry ([@B39])                                                                                                                          Prevention of ALI in SARS-CoV-infected mice ([@B54])Cardiac  protection:  ACE2  and Ang-(1-7) increase in autoimmune myocarditis in rats ([@B101])                                                                           Increased ACE2 and Ang-(1-7) in hypertensive patients ([@B31])Reduced risk of pneumonia in type 1 and type 2 diabetic patients ([@B107])   Diminished risk of severe COVID-19 in ARB-treated patients ([@B70])Lower concentrations of CRP and procalcitonin in ACEi/ARB treated patients ([@B126])≥ 20 registered clinical trials: CAPTOCOVID (NCT04355429), RAMIC (NCT04366050), NCT04345406 (capto/enalapril), NCT04355936 (telmisartan).
  **ARBs**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Ang-(1-7) analogues**   Vasodilatory and cytoprotective effects as anti- inflammatory, -oxidant, -proliferative, -thrombotic, -senescent ([@B91]; [@B90])                      Anti-inflammatory and anti-fibrotic effects in ALI and ARDS models ([@B50]; [@B91])Prevention  of  cardiac  fibrosis  in SD rats ([@B36])Impaired  leukocyte  adhesion  to microvascular endothelium in arthritis ([@B98])                                                                                                                                              ATCO (NCT04332666)TXA127 COVID (NCT04401423)NCT04375124 (Ang-(1-7) vaccine)

  **rhACE2**                Block SARS-CoV-2 infection in Vero cells, human blood vessels and kidney organoids ([@B71])Recovered Ang II levels in human isolated hearts ([@B12])   Blood  pressure  decrease  and improved endothelial function in SHSRP rats ([@B30])Improved  pulmonary  arterial compliance in pulmonary hypertension ([@B40])                                                               Phase  II  clinical  trial  for ARDS/ALI (NCT01597635)                                                                                     APN01-COVID-19 (NCT04335136)Bacterial ACE2 (NCT04375046)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Similarly, in the case it is confirmed that DPP4 plays a role in SARS-CoV-2 infection as co-receptor, the use of sDPP4 as decoy receptor could also be explored. However, in obesity and T2DM sDPP4 levels are upregulated, sDPP4-induced immunomodulatory actions might be altered and there is a reduced bioavailability of beneficial substrates, facing COVID-19 CV consequences might be a difficult task. Other potential therapeutic approaches worth exploring are DPP4i in order to determine if they can block virus entry, as described for sitagliptin in MERS. Irregardless of DPP4 role as co-receptor, gliptins might help prevent CV complications in COVID-19 due to their anti-inflammatory effects at vascular level. Anti-DPP4 vaccine has been proven effective in mice to control glucose homeostasis and might represent another potential approach.

In conclusion, further preclinical research and clinical data will help to better understanding of the SARS-CoV-2 virus ([**Table 2**](#T2){ref-type="table"}), and will allow to determine if any of these potential therapeutic strategies is useful.

###### 

Summarized effects of sDPP4-targeted drugs (gliptins, sDPP4 and DPP4 vaccine) reported in preclinical (*in vivo* and *ex vivo*) and clinical research.

                          Preclinical data                                                                                                                                                                                                       Previous clinical trials                                                                                                                                                                                                                                                                                 COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ----------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  **Gliptins**            Block MERS-CoV infection in macrophages ([@B3])Prevention of sDPP4-induced hVSMC proliferation and inflammation ([@B119])                                                                                              Prevention of sDPP4-induced endothelial dysfunction in mice ([@B88])Anti-oxidant effects in STZ-induced diabetic rats and LPS-induced sepsis mouse model, respectively ([@B67]; [@B14])Reduction of NLRP3/ASC inflammasome activation in db/db mice ([@B17])Improved cardiac function in mice ([@B81])   Decreased  risk  of  non-fatal  CV  events and CV mortality ([@B113])No risk of infection in type 1 and type 2 diabetic patients ([@B124])Increased  cardio  and  vasculoprotective substrates ([@B19]; [@B93]; [@B28])Anti-inflammatory effects in type 2 dibatec patients ([@B68]; [@B104])Improved  flow-mediated  vasodilation  in diabetic patients ([@B11])Potential induction of leucopenia, angioedema, cough and asthma ([@B35]; [@B10])   SIDIACO Sitagliptin (NCT04365517)Linagliptin: NCT04371978, NCT04341935
  **sDPP4**               Block MERS-CoV infection in Vero cells ([@B85])hVSMC proliferation and inflammation ([@B119])Pro-inflammatory effects ([@B119]; [@B88])Inhibition of T-cell activation and proliferation *via* ADA binding ([@B129])   Endothelial dysfunction in murine mesenteric microvessels ([@B88])Increased monocyte migration in LDLR-/- mice ([@B95])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Direct  truncation  of CCL5/RANTES: reduced IL-6 levels and viremia ([@B46]; [@B78])
  **Anti-DPP4 vaccine**   Blockade of MERS-CoV infection ([@B75])No effects on T-cell proliferation or cytokine production ([@B5])                                                                                                               Increased GLP-1 in type 1 and type 2 diabetic mice ([@B77]; [@B61])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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[^1]: Edited by: Dieter Steinhilber, Goethe University Frankfurt, Germany

[^2]: Reviewed by: Lu Cai, University of Louisville, United States; Kristen Bubb, Monash University, Australia; Chris R. Triggle, Weill Cornell Medicine, Qatar

[^3]: This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
